Board

Martin G. Baum – President, Chairman and Chief Executive Officer

Martin Baum has been involved in the pharmaceutical and biotechnology industries for more than 20 years. He began his career with Merrell Dow Pharmaceuticals and subsequently moved through the ranks at GlaxoSmithKline Pharmaceuticals. He later transitioned his career to Skye Pharma, PLC. Mr. Baum was instrumental in starting three brand pharmaceutical companies including, Brightstone Pharma, DJ Pharma, and TEAMM Pharmaceuticals, Inc. At DJ Pharma, Mr. Baum held the position of Senior Vice President, Commercial Operations from December 1998 until July 2000. Under Mr. Baum’s direction, the company achieved net revenue in excess of $60 million and profitability within two years. The company was sold to Biovail Corporation in October 2000, for $212 million. Based on his success at DJ Pharma, Mr. Baum founded TEAMM. At TEAMM, he was President and Chief Executive Officer. He later orchestrated the company’s sale to Accentia Biopharma. While at Accentia, Mr. Baum served as company COO and directed the initiative to take Accentia public. Mr. Baum has extensive industry experience from conceptual product design to product commercialization. In addition, he has developed strong business relationships within the financial markets, having raised over $250M during his tenure, while developing these companies. He has worked closely in all stages of FDA product approvals, medical device approvals, drug delivery technology development and generic product market entries. He has successfully led companies to continued growth, through numerous business cycles. Mr. Baum is a graduate of The University of Toledo, with B.S. degrees in Human Life Sciences and Business Administration.

Steve Lutz – Chief Operating Officer

Steve has had an exceptional career in all aspects of pharma business and commercialization. A founder of Praelia Pharmaceuticals, Steve was able to direct and develop a new health care entity into both the consumer and prescription pharmaceutical arenas.   With Cornerstone Therapeutics, Steve was Executive Vice President, of Operations as well as a founding stockholder. He was President of Aristos, Cornerstone’s generics division and achieved $40m of net profit in its first two years of operations. Steve has held various executive positions in the industry including Director, Trade Sales for Verum and acted as National Account Manager for both Biovail and Shire.  Steve holds a B.A. in Political Science and Sociology from Moravian College in Bethlehem, Pennsylvania.